FIELD: biotechnology.
SUBSTANCE: invention relates to biotechnology, specifically to a method of treating or inhibiting tumour growth in a patient with cervical cancer, involving selecting a patient with recurrent or metastatic cervical cancer and with disease progression with underlying or following platinum-based chemotherapy and administering to the patient an antibody or an antigen-binding fragment thereof, which specifically binds to programmed cell death protein 1 (PD-1), as a monotherapy in dose of 350 mg every 3 weeks. Also disclosed is a method for improving overall survival of a patient with cervical cancer, involving selecting a patient with recurrent or metastatic cervical cancer and progression of the disease with underlying or after platinum-based chemotherapy and administering an antibody or an antigen-binding fragment thereof, which specifically binds to programmed cell death protein 1 (PD-1), as monotherapy in dose of 350 mg every 3 weeks.
EFFECT: invention is effective for treating or inhibiting tumour growth in a patient with recurrent or metastatic cervical cancer and disease progression with underlying or following platinum-based chemotherapy.
33 cl, 9 dwg, 31 tbl, 5 ex
| Title | Year | Author | Number |
|---|---|---|---|
| ANTIBODIES AGAINST PD-1 FOR TREATMENT OF LUNG CANCER | 2018 |
|
RU2771759C2 |
| USE OF ANTI-PD-1 ANTIBODY IN PREPARATION OF MEDICINAL AGENT FOR TREATING SOLID TUMOURS | 2020 |
|
RU2825845C2 |
| METHOD FOR TREATMENT OF MALIGNANT NEOPLASM, USING COMBINATION OF ANTIBODY TO PD-1 AND CHEMOTHERAPEUTIC AGENT | 2021 |
|
RU2787457C2 |
| PD-1/PD-L1 INHIBITORS FOR TREATING CANCER | 2016 |
|
RU2714233C2 |
| APPLICATION OF AN ANTIBODY TO PD-1 IN COMBINATION WITH FAMITINIB FOR PRODUCING A MEDICINAL PRODUCT FOR TREATING TUMOURS | 2019 |
|
RU2783846C1 |
| METHODS OF TREATING CANCER USING ANTI-PD-1 ANTIBODIES AND ANTI-CTLA4 ANTIBODIES | 2019 |
|
RU2825835C2 |
| TIGIT ANTIBODY ADMINISTRATION REGIMEN FOR TREATING CANCER | 2019 |
|
RU2833669C2 |
| ISOLATED BISPECIFIC ANTIBODY THAT SPECIFICALLY BINDS TO CD47 AND PD-L1 | 2021 |
|
RU2815823C2 |
| ANTI-GDF15 ANTIBODIES, COMPOSITIONS AND METHODS OF USE | 2019 |
|
RU2795457C2 |
| ANTI-PD-L1 ANTIBODY AND ITS USE | 2020 |
|
RU2783685C2 |
